2023
Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-analysis of Primary Patency and Binary Restenosis Rates.
Snyder D, Zilinyi R, Pruthi S, George S, Tirziu D, Lansky A, Mintz A, Sethi S, Parikh S. Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-analysis of Primary Patency and Binary Restenosis Rates. Journal Of Endovascular Therapy 2023, 15266028231212133. PMID: 38008929, DOI: 10.1177/15266028231212133.Peer-Reviewed Original ResearchChronic limb-threatening ischemiaPercutaneous transluminal angioplastyBinary restenosis ratePrimary patencyPrimary patency rateBinary restenosisTransluminal angioplastyRestenosis rateFuture RCTsPatency ratesTrial dataChronic limb threatening ischemiaLimb threatening ischemiaLimb-threatening ischemiaRandom-effects modelMeta-analysis demonstrateIntermittent claudicationEndovascular therapyCochrane CENTRALPower calculationMeta-analysis estimatesControl armPatencyRCTsSystematic reviewPersuasive COVID-19 vaccination campaigns on Facebook and nationwide vaccination coverage in Ukraine, India, and Pakistan
Winters M, Christie S, Lepage C, Malik A, Bokemper S, Abeyesekera S, Boye B, Moini M, Jamil Z, Tariq T, Beresh T, Kazymyrova G, Palamar L, Paintsil E, Faller A, Seusan A, Bonnevie E, Smyser J, Khan K, Gulaid M, Francis S, Warren J, Thomson A, Omer S. Persuasive COVID-19 vaccination campaigns on Facebook and nationwide vaccination coverage in Ukraine, India, and Pakistan. PLOS Global Public Health 2023, 3: e0002357. PMID: 37756298, PMCID: PMC10529538, DOI: 10.1371/journal.pgph.0002357.Peer-Reviewed Original ResearchVaccine uptakeVaccination coverageCOVID-19 vaccination campaignCOVID-19 vaccine uptakeMessaging campaignsWeeks of interventionCOVID-19 vaccination dataPoisson regression modelsVaccination statusPre-post designVaccination dataVaccination intentionVaccination campaignTime pointsWeeksInterventionRCTsVaccineImportant predictorRegression modelsOffline effectsRobust evidenceUptakeTrialsA Mixed-Methods Implementation Evaluation of Virtual Reality Job Interview Training in IPS Supported Employment
Blajeski S, Smith M, Harrington M, Johnson J, Ross B, Weaver A, Razzano L, Pashka N, Brown A, Prestipino J, Nelson K, Lieberman T, Jordan N, Oulvey E, Mueser K, McGurk S, Bell M, Smith J. A Mixed-Methods Implementation Evaluation of Virtual Reality Job Interview Training in IPS Supported Employment. Psychiatric Services 2023, 75: 228-236. PMID: 37644829, PMCID: PMC10902191, DOI: 10.1176/appi.ps.20230023.Peer-Reviewed Original ResearchSerious mental illnessMental illnessMixed methods implementation evaluationIPS Supported EmploymentCommunity mental health agenciesImplementation evaluationMental health agenciesTechnology-based interventionsVirtual reality job interview trainingIllnessHealth agenciesVR-JITQuantitative findingsIndividual PlacementRecipientsSupported EmploymentFeasibility surveyMixed methods designFocus groupsStaffIndividualsFindingsDeliveryAcceptabilityRCTsTherapeutic developments for valosin-containing protein mediated multisystem proteinopathy
Boock V, Roy B, Pfeffer G, Kimonis V. Therapeutic developments for valosin-containing protein mediated multisystem proteinopathy. Current Opinion In Neurology 2023, 36: 432-440. PMID: 37678339, DOI: 10.1097/wco.0000000000001184.Peer-Reviewed Original ResearchConceptsInclusion body myopathyPotential therapeutic targetValosin-containing proteinPaget's diseasePreclinical modelsTherapeutic approachesPotential therapyControl trialRare diseaseTherapeutic targetBody myopathyVivo modelFrontotemporal dementiaVCP mutationsMultisystem proteinopathyPathway involvementDiseaseTherapyMitochondrial dysfunctionTherapeutic developmentGene therapyMissense mutationsFunction activityATPase activityRCTsRepresentativeness of Peripheral Artery Disease Randomized Clinical Trials Supporting Current Guidelines
Castro-Dominguez Y, Mena-Hurtado C, Algara M, Obas V, Ahmed Z, Romain G, Solaru K, Smolderen K. Representativeness of Peripheral Artery Disease Randomized Clinical Trials Supporting Current Guidelines. The American Journal Of Cardiology 2023, 201: 166-169. PMID: 37385170, DOI: 10.1016/j.amjcard.2023.05.053.Peer-Reviewed Original ResearchConceptsPeripheral artery diseasePAD guidelinesArtery diseaseRecent American Heart Association/American CollegeAmerican Heart Association/American CollegeLower extremity peripheral artery diseaseOlder adult patientsRace/ethnicity distributionAdult patientsPooled proportionMean ageClinical trialsCurrent guidelinesEpidemiologic studiesAmerican CollegeTrial participantsRCTsEthnicity distributionOlder adultsTrialsWomenPatientsDiseaseGuidelinesEthnic groups
2022
Early palliative care in newly diagnosed cancer in Ethiopia: feasibility randomised controlled trial and cost analysis
Reid E, Abathun E, Diribi J, Mamo Y, Wondemagegnhu T, Hall P, Fallon M, Grant L. Early palliative care in newly diagnosed cancer in Ethiopia: feasibility randomised controlled trial and cost analysis. BMJ Supportive & Palliative Care 2022, 14: e504-e507. PMID: 36414402, DOI: 10.1136/spcare-2022-003996.Peer-Reviewed Original ResearchEarly palliative careStandard cancer carePalliative careCancer careHome palliative careStandard careMiddle-income countriesPrimary outcomeFeasibility trialCancer deathPC outcomesStudy visitStage IIICare subjectsInformal caregiversCareCancerTrialsAddis AbabaPocket paymentsPatientsPC researchPOS useOutcomesRCTsClinical Research on Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve Disease: Principles, Challenges, and an Agenda for the Future
Ahmad Y, Madhavan M, Baron S, Forrest J, Borger M, Leipsic J, Cavalcante J, Wang D, McCarthy P, Szerlip M, Kapadia S, Makkar R, Mack M, Leon M, Cohen D. Clinical Research on Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve Disease: Principles, Challenges, and an Agenda for the Future. Structural Heart 2022, 7: 100102. PMID: 37275317, PMCID: PMC10236801, DOI: 10.1016/j.shj.2022.100102.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementBicuspid aortic valve diseaseSurgical aortic valve replacementAortic valve replacementAortic valve diseaseValve replacementClinical researchValve diseaseValvular heart diseaseDesign of RCTsProcedural therapiesProspective registryHeart diseaseExclusion criteriaRisk scorePatientsRCTsDiseaseCardiovascular communityMultidisciplinary workshopSelection biasTrialsInternational expertsPotential studiesRegistryInterventions Targeted to Address Social Determinants of Health in Ischemic Heart Disease: A Sex- and Gender-Oriented Scoping Review
Raparelli V, Wright CX, Corica B, Sharma G, Lindley K, Brackett A, Pilote L, Wood MJ, Dreyer RP. Interventions Targeted to Address Social Determinants of Health in Ischemic Heart Disease: A Sex- and Gender-Oriented Scoping Review. Canadian Journal Of Cardiology 2022, 38: 1881-1892. PMID: 35809812, DOI: 10.1016/j.cjca.2022.06.025.Peer-Reviewed Original ResearchConceptsIschemic heart diseaseHealth care systemHeart diseaseCare systemPatient education interventionsMajor health problemSex-stratified analysesSocial supportSDOH interventionsIHD patientsMale patientsSDOH domainsMinority patientsCare implementationHealth literacyPatientsHealth problemsRCTsSocial determinantsReporting of findingsInterventionSuch interventionsSDOHScoping ReviewSocioeconomic determinantsRacial and ethnic differences in alcohol, cannabis, and illicit substance use treatment: a systematic review and narrative synthesis of studies done in the USA
Jordan A, Quainoo S, Nich C, Babuscio TA, Funaro MC, Carroll KM. Racial and ethnic differences in alcohol, cannabis, and illicit substance use treatment: a systematic review and narrative synthesis of studies done in the USA. The Lancet Psychiatry 2022, 9: 660-675. PMID: 35752192, DOI: 10.1016/s2215-0366(22)00160-2.Peer-Reviewed Original ResearchConceptsSubstance use outcomesTreatment initiationJoanna Briggs Institute appraisal toolsSystematic reviewSubstance use disordersSignificant differencesSubstance use treatmentDissemination of treatmentUncontrolled trialsClinical trialsBaseline differencesStudy qualityInclusion criteriaUse disordersRCTsNarrative synthesisSocial determinantsUse treatmentAppraisal toolLatinx adultsEthnic differencesEthnic populationsOutcomesTrialsLatinx populationsAgreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study
Moneer O, Daly G, Skydel JJ, Nyhan K, Lurie P, Ross JS, Wallach JD. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study. The BMJ 2022, 377: e069400. PMID: 35537738, PMCID: PMC9086409, DOI: 10.1136/bmj-2021-069400.Peer-Reviewed Original ResearchConceptsCOVID-19 treatmentObservational studyMeta-epidemiological studyEfficacy outcomesLopinavir-ritonavirLiving reviewTreatment effectsCOVID-19 treatment guidelinesSame interventionCOVID-19Continuous outcomesMeta-analyze evidenceTrial sequential analysisSummary treatment effectsDistribution of sexTreatment guidelinesIndividual RCTsSelection of studiesEvidence DatabasePlacebo comparatorClinical dataStudy demographicsRCTsDichotomous outcomesTherapeutic interventionsMeta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders
Behling E, Farhat LC, Landeros‐Weisenberger A, Bloch MH. Meta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders. Movement Disorders 2022, 37: 684-693. PMID: 35191552, DOI: 10.1002/mds.28957.Peer-Reviewed Original ResearchConceptsChronic tic disorderTourette syndromeVMAT2 inhibitorsTic disordersVesicular monoamine transporter type 2 inhibitorsYale Global Tic Severity ScaleMean differenceRate of discontinuationTic Severity ScaleType 2 inhibitorsShort-term treatmentTic symptomsBlinded RCTEffective therapySeverity ScaleSystematic reviewTolerabilityAvailable evidenceAdverse effectsInverse varianceEfficacyRCTsInhibitorsNonsignificant effectTrials
2021
Patient representativeness of a peripheral artery disease cohort in a randomized control trial versus a real-world cohort: The CLEVER trial versus the PORTRAIT registry
Scierka LE, Jelani QU, Smolderen KG, Gosch K, Spertus JA, Mena-Hurtado C, Jones P, Dreyer RP. Patient representativeness of a peripheral artery disease cohort in a randomized control trial versus a real-world cohort: The CLEVER trial versus the PORTRAIT registry. Contemporary Clinical Trials 2021, 112: 106624. PMID: 34793986, DOI: 10.1016/j.cct.2021.106624.Peer-Reviewed Original ResearchConceptsOptimal medical therapyPeripheral artery diseasePatient characteristicsBaseline patient characteristicsPAD cohortPAD populationPORTRAIT registryExercise therapyPAD patientsPAD symptomsArtery diseaseFinal cohortMedical therapyProspective studyBurdensome diseaseControl trialHealth statusPatientsTherapyCohortCLEVER studyDiseaseMulticenterRevascularizationRCTsInvestigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review
Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2021, 78: 1635-1654. PMID: 34649702, PMCID: PMC8504484, DOI: 10.1016/j.jacc.2021.08.021.Peer-Reviewed Original ResearchConceptsLipid-modulating agentsEndothelial activationLow high-density lipoprotein cholesterolCOVID-19High-density lipoprotein cholesterolLipid modulating agentsHigh triglyceride levelsMultiorgan manifestationsStatin trialsLipoprotein cholesterolSystemic inflammationTriglyceride levelsJACC StateWorse outcomesInflammatory responsePatient managementRCTsCoronavirus diseaseViral entrySystematic searchLipid raft disruptionTrialsPatientsRaft disruptionPreventionFinancial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials
Metzger AL, Appiah A, Wright CM, Jairam V, Amini A, Park HS, Welsh JW, Thomas CR, Verma V, Ludmir EB. Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials. International Journal Of Cancer 2021, 149: 1683-1690. PMID: 34173669, DOI: 10.1002/ijc.33719.Peer-Reviewed Original ResearchConceptsClinical trialsMultivariable gamma regression analysesNational Clinical Trials NetworkPrincipal investigatorPhase III componentSystemic therapy trialsUS cooperative groupsClinical Trials NetworkCooperative groupsCancer clinical trialsGamma regression analysisSystemic therapySuch RCTsTherapy trialsRCTsTrials NetworkTrialsRegression analysisOne-thirdMedical journalsDrugsComparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis
Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L’Italien G, Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Review Of Pharmacoeconomics & Outcomes Research 2021, 22: 155-166. PMID: 34148501, DOI: 10.1080/14737167.2021.1945444.Peer-Reviewed Original ResearchConceptsPain freedomAcute treatmentAdverse eventsLow dosesSustained pain freedomAbsence of headFixed-effect Bayesian NMAHigh rateStudy 303Acute migraineEfficacy outcomesPain reliefBayesian NMAEfficacy resultsLasmiditanACHIEVE IComparative efficacyHigh dosesHead comparisonRCTsMigraineDosesRelative efficacySomnolenceOutcomesCharacteristics of Randomized Clinical Trials in Surgery From 2008 to 2020
Robinson NB, Fremes S, Hameed I, Rahouma M, Weidenmann V, Demetres M, Morsi M, Soletti G, Di Franco A, Zenati MA, Raja SG, Moher D, Bakaeen F, Chikwe J, Bhatt DL, Kurlansky P, Girardi LN, Gaudino M. Characteristics of Randomized Clinical Trials in Surgery From 2008 to 2020. JAMA Network Open 2021, 4: e2114494. PMID: 34190996, PMCID: PMC8246313, DOI: 10.1001/jamanetworkopen.2021.14494.Peer-Reviewed Original ResearchConceptsMost trialsClinical eventsSurgical interventionSurgical RCTsClinical trialsSurgeon experienceMinor clinical eventsMore surgical interventionsReporting biasMajor clinical eventsRandomized clinical trialsRisk of biasMedian fragility indexMedian sample sizeLarge treatment effectsPrimary outcomeTRIAL REGISTRATIONControl armTrial characteristicsSurgical trialsHigh riskSuperiority designConcerns of biasPrimary analysisRCTsMisreporting of Results of Research in Psychiatry
Bowcut J, Levi L, Livnah O, Ross JS, Knable M, Davidson M, Davis JM, Weiser M. Misreporting of Results of Research in Psychiatry. Schizophrenia Bulletin 2021, 47: 1254-1260. PMID: 33860793, PMCID: PMC8379531, DOI: 10.1093/schbul/sbab040.Peer-Reviewed Original ResearchLong-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal Of Substance Use And Addiction Treatment 2021, 128: 108389. PMID: 33865691, PMCID: PMC8384640, DOI: 10.1016/j.jsat.2021.108389.Peer-Reviewed Original ResearchConceptsOpioid use disorderSelf-reported opioid useOpioid-positive urine samplesExtended-release buprenorphineExtended-release naltrexoneOpioid overdose eventsXR-NTXOpioid treatmentObservational cohortOpioid useUsual armCare outcomesUse disordersNoninferiority designOverdose eventsUrine samplesBuprenorphineTreatmentAdultsEnhanced treatmentNaltrexoneRCTsCohortU.S. localesTrialsPublication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade
Peters GW, Tao W, Wei W, Miccio JA, Jethwa KR, Cecchini M, Johung KL. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. The Oncologist 2021, 26: 660-667. PMID: 33728733, PMCID: PMC8342580, DOI: 10.1002/onco.13759.Peer-Reviewed Original ResearchConceptsGI oncologyPublication biasImpact of RCTsFuture trial designMultivariable logistic regressionSignificant publication biasPast trialsAccrual completionCancer RCTsEvidence-based practiceGastrointestinal cancerClinical managementTrial completionTrial designOncology trialsClinical practicePublication statusRCTsTrial questionModern RCTsLogistic regressionHalf of trialsTrialsPhase IIIGold standardIs there evidence for using anticonvulsants in the prevention and/or treatment of delirium among older adults?
Gupta A, Joshi P, Bhattacharya G, Lehman M, Funaro M, Tampi DJ, Tampi RR. Is there evidence for using anticonvulsants in the prevention and/or treatment of delirium among older adults? International Psychogeriatrics 2021, 34: 889-903. PMID: 33757611, DOI: 10.1017/s1041610221000235.Peer-Reviewed Educational MaterialsConceptsTreatment of deliriumTotal knee arthroplastyTotal hip arthroplastyPostoperative deliriumUse of anticonvulsantsPerioperative useSpinal surgeryOlder adultsElective total knee arthroplastyElective total hip arthroplastyUse of gabapentinCochrane Central RegisterAnalysis of RCTsPerioperative gabapentinCentral RegisterKnee arthroplastyHip arthroplastyDeliriumCurrent evidenceGabapentinRCTsAnticonvulsantsSystematic reviewArthroplastyComprehensive search
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply